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Objectives: To assess initial experience with the use of a new SPECT-CT in the 
evaluation of lesions. 
Methods: The folder number, radiopharmaceutical used and type of scan of patients 
examined with a new Siemens T6 SPECT-CT between 2 April and 31 December 2013 
were retrieved. The number of 99mTc-MDP bone scans was sufficient for a detailed 
analysis. The scans were re-processed and reported by the observer before he was 
given any clinical information.  Whole body planar, whole body planar plus SPECT 
and whole body planar plus SPECT-CT images were assessed successively in three 
separate sessions at least two weeks apart.  At each session, the certainties of 
detection, localisation, and categorisation of each lesion were recorded. 
Results: A total of 539 lesions were seen on the whole body, SPECT and CT images 
in 133 patients.  The whole body images showed no lesions in three patients and 
378 lesions in 130 patients, 117(31%) lesions in areas not covered by the SPECT. 
SPECT detected 122 additional lesions in 79 patients. Thirty-nine (12.2%) lesions 
were seen only on CT in 32 (24.1%) patients.  
For the 261 lesions seen on the planar images in the SPECT FOV, lesion detection 
was definite in 233 (89.3%), localisation definite in 151(57.9%) and categorisation 
definite in 123 (47.1%) lesions. On the SPECT, definite lesion detection, localisation 
and categorisation were recorded respectively for 259 (99.2%), 228 (87.4%) and 
176 (67.4%) of the 261 lesions. Lesion detection, localisation and categorisation 




Conclusion: Whole body planar scintigraphy is essential in lesion detection. SPECT 




1.0 RESEARCH PROTOCOL 
This research protocol was submitted to the Faculty of Health Sciences, University 
of Cape Town before commencement of the study. 
1.1 Background 
The use of hybrid imaging consisting of Single Photon Emission Computerized 
Tomography (SPECT) and X-ray transmission Computerized Tomography (CT) scan 
is increasing globally. This mode of hybrid imaging has the advantage of providing 
functional and morphologic information for a given lesion or pathology in a single 
session. The aim of this study is to see to what extent the addition of SPECT and 
SPECT-guided multi-slice CT affects categorization of lesions demonstrated on 
conventional static planar imaging in the department of nuclear medicine at Groote 
Schuur Hospital. 
1.2 Literature review 
Radionuclide imaging by the use of SPECT is currently an important component of 
evaluation of various diseases with a high degree of sensitivity due to its ability to 
provide functional information early in the disease even before morphological 
changes become visible on other imaging modalities.1,2 However, the limited spatial 
resolution of SPECT necessitated the introduction of X-ray based computerized 
tomography which has superior spatial resolution and provides morphologic 
information that helps in better localization of lesions seen on functional and 
metabolic imaging. This form of hybrid imaging has improved the staging of disease 
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as well as the prognostic and treatment monitoring potentials of the functional and 
metabolic information provided by conventional nuclear medicine examinations.3,4 
There is dearth of literature reporting the utility, sensitivity, specificity and accuracy 
of this imaging technique as it applies to non-skeletal nuclear medicine 
examinations. 
 
In a report of initial two-year clinical experience with SPECT-CT by Jacene et al, 54% 
of the cases studied had additional information for image interpretation derived 
from the fusion of the SPECT with the CT images mostly as a result of improved 
localization of abnormal and physiologic SPECT findings by the CT data.3 This study 
also reported improved diagnostic certainty in 24% of the cases and beneficial 
alteration of image interpretation in 13% of the cases. However, some of the 
limitations reported in this study included the low-resolution single-slice CT used 
which did not reveal the exact anatomical sites of abnormal radiotracer 
accumulation especially in the interpretation of abdominal findings on 111In-
Pentetreotide scans, as well as the prolonged CT acquisition time of 10-15 minutes 
by the single-slice scanners that resulted in increased patient motion and 
degradation of image quality. Prolonged acquisition time has been addressed by the 
recent introduction of multi-slice CTs in newer versions of the SPECT-CT systems.4  
 
The new SPECT-CT in the department of Nuclear Medicine at Groote Schuur 
Hospital is equipped with a six-slice multi-detector CT which is likely to overcome 
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some of the limitations reported in the use of single slice CT, hence the need for this 
research.  
 
Over the years, the main advantages of hybrid SPECT-CT imaging included accurate 
localization and characterization of endocrine and neuroendocrine tumors, solitary 
pulmonary nodules, lung cancers, brain tumors, lymphoma, prostate cancer, 
malignant and benign bone lesions, sentinel lymph node localization as well as 
precise definition of the diagnostic and prognostic profile of cardiovascular 
patients.4 Adaptation of the CT field of view to foci of increased bone metabolism in 
a technique referred to as SPECT-guided CT has been shown to accurately classify 
previously indeterminate lesions on planar and SPECT imaging in the axial skeleton 
with certainties of 92% to 100%.5–7 These studies limited their observations to the 
evaluation of foci of increased bone metabolism classified as indeterminate on 
SPECT in cancer patients, therefore inclusion of other systems in the evaluation of 
the clinical value of SPECT-CT is likely to reveal some of its potentials. 
 
In a review by Mohan et al on the assessment of the additional value of SPECT-CT 
amongst patients referred from the orthopaedic clinics, it was observed that when 
compared with planar imaging, SPECT-CT provided additional information in 81% 
of the patients.8 SPECT-CT provided specific diagnosis in 46% of the patients in this 
series, and more accurate localization of degenerative or post-surgical changes in 
the remaining 54% of the patients. This is similar to findings by Langroudi et al and 
Mohan et al, in studies comparing SPECT-CT with planar imaging in the evaluation 
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of foot and ankle pathology.9,10 Images acquired with a 16-slice CT were used in 
these studies.  
 
Ndlovu et al reported a SPECT-CT accuracy of 52% in a study of cancer patients with 
equivocal lesions on planar bone imaging for skeletal metastases.11 This study 
recommended the utilization of SPECT-CT in the evaluation of equivocal lesions in 
instances where correct classification of lesions is expected to alter the patient’s 
management regardless of the tumor primary or presence of bone pain. The type of 
CT scanner used in this study was not mentioned. 
 
Report of comparison of planar imaging with SPECT/16-multislice CT (MSCT) 
among paediatric patients by Andersen et al, showed that additional structural 
information was gained in 93% of the cases and additional nuclear medicine 
information was gained in 80% of the cases, while specific information for biopsy 
guidance was gained in 40% of the cases studied.12 
 
1.3 Objectives 
1. To assess the initial experience with the use of SPECT-guided CT in the 
evaluation of lesions since the installation of SPECT-CT in the Nuclear 
Medicine department at Groote Schuur Hospital in 2012. 
2. To assess the impact of the addition of 6 slice CT in SPECT-CT on lesion 
categorization. 
11 
3. To assess whether or not, there is significant difference between the use of
SPECT alone and fused SPECT-CT in lesion categorization.
1.4 Methods 
1.4.1 Study design 
The study will involve retrospective evaluation of SPECT-CT examinations 
performed in the department of nuclear medicine of the Groote Schuur Hospital 
from April 2012 to December 2013. Currently, there are 139 SPECT-CT scans 
conducted for diagnostic purposes that are eligible for inclusion into the study. This 
number is expected to increase to about 200 by December 2013. Therefore, about 
200 cases will be included in the study. 
1.4.2 Materials 
All patients were examined on a stand-alone Symbia T6 SPECT-CT system (Siemens 
Medical Solutions). Some of the patients were initially scanned on the Siemen’s 
eCam Signature series dual head gamma camera and later transferred to the stand-
alone Symbia hybrid SPECT-CT for a SPECT-guided CT acquisition based on lesions 
found on the initial planar and SPECT images. Examinations will be processed and 
analyzed on the Siemens physicians’ workstations.  
1.4.3 Subjects 
Patients were referred to the nuclear medicine department for 99mTc-MDP bone 
scintigraphy, 123Iodine/131Iodine diagnostic scan, 131Iodine post-therapy scan, 
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123Iodine metaiodobenzyl guanidine (123I-MIBG) scan, parathyroid scintigraphy, 
99mTc-Octreotide scan for suspected neuroendocrine tumors, infection imaging and 
sentinel lymph node localization. The original raw SPECT-CT data of patients will be 
retrieved from the archives and re-processed for analysis. 
 
1.4.4 Inclusion criteria 
SPECT examinations conducted between April 2012 and December 2013 that had 
CT scans performed as result of lesions observed in the initial part of the study as 
well as studies with clear cut indications for the need to use CT data in order to aid 
localization. 
 
1.4.5 Exclusion criteria 
1. Examinations with poor technical quality 
2. Examinations with poor co-registration of the SPECT and CT data 
3. All SPECT myocardial perfusion studies 
4. All SPECT cerebral perfusion studies 
 
1.4.6 Ethical issues 
The study is retrospective in nature and shall involve analysis of routine 
examinations conducted following protocols derived from already established 
standard international guidelines on the use of radiopharmaceuticals and SPECT-CT 
imaging according to the Society of Nuclear Medicine (SNM) and European 
Association of Nuclear Medicine (EANM).13–15 The radiation dose to the patient was 
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not increased at all because no additional imaging was done in the course of the 
study. Patients’ confidentiality will be observed throughout the study by the use of a 
coding system and in compliance with Helsinki declaration.16 Patients’ names will 
not be used in the study or the final report at the end of the study.  
The patients’ data to be used in the study is from the Nuclear Medicine database 
already registered by the Human Research Ethics Committee of the Faculty of 
Health Sciences with reference number: R006/2012 (see copy of approval attached, 
appendix I). 
 
1.4.7 Data collection  
The observer is blinded to the history, clinical examinations, laboratory and 
histology results as well as the previous reports issued. Patients’ age and sex will be 
recorded. The type of nuclear medicine study, images acquired (static planar, SPECT 
and SPECT-CT) will be retrieved from the archives, re-processed and reviewed. The 
location and number of lesions observed from the studies as well as level of 
diagnostic certainty will be recorded. In patients referred for bone scan for 
malignant disease, the lesions will be categorized successively in separate reading 
sessions on planar, SPECT and SPECT-CT images using a 3-point scoring system: 
1=benign; 2=indeterminate and 3= malignant. An appropriate classification will be 
used for the remaining types of scans. Lesions will simultaneously be further sub-
categorized based on the level of diagnostic certainty, which will be graded on a 




A time difference of at least 2 weeks in-between the independent interpretations of 
the planar alone, planar plus SPECT and fused SPECT-CT images will be allowed. A 
single observer who will be blinded to the previously issued report of the 
examinations will carry out the interpretations. Comparison will then be made 
between the final results and the report issued to the referring clinicians, which was 
interpreted by qualified nuclear medicine physicians and radiologists. 
 
Data will be analyzed for sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy for planar, planar plus SPECT and SPECT-CT sub-
groupings where possible. Comparison will be made between the groups. 
Assessment will be made of improvements or lack of, on lesion localization, 
categorization and diagnostic certainty. 
 
1.5 Limitations 
The study being retrospective in nature is a limitation. 
A single observer will be involved in the study due to time constraints. 
Histological validation will not be included in this study.  
 
1.6 Funding 
All imaging results to be reviewed were part and parcel of routine patient 
examinations for treatment. Therefore, no funding is required in this regard. The 
researcher will personally fund the purchase of the stationaries as well as 
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2.0 LITERATURE REVIEW 
 
2.1 Objectives Of Literature Review 
The objectives of this study were to assess the initial experience with the use of a 
new SPECT- CT in the evaluation of lesions; the impact of the addition of 6-slice CT 
on lesion categorization, and the difference between the use of SPECT alone and 
fused SPECT-CT in lesion localization and categorization. 
The main objective of this literature review is to identify studies on the use of 
SPECT-CT on lesion categorization as well as its impact on observer’s confidence 
and management outcome.  
 
2.2 Literature search strategy 
Internet search of PubMed and Google scholar databases was undertaken. Key 
phrases searched were single photon emission computerized 
tomography/computerized tomography AND lesion categorization OR 
characterization. Studies considered for review include: comparison of SPECT-CT 
versus SPECT scintigraphy alone, SPECT-CT versus SPECT versus planar 
scintigraphy, and SPECT-CT in patients with indeterminate lesions on conventional 




2.3 Literature  
The use of hybrid imaging consisting of Single Photon Emission Computerized 
Tomography (SPECT) and X-ray transmission Computerized Tomography (CT) scan 
is increasing globally. This mode of hybrid imaging has the advantage of providing 
functional and morphologic information for a given lesion or pathology in a single 
session. SPECT image acquisition improves lesion detection when compared to two-
dimensional planar imaging by removing out-of-plane information thereby 
increasing image contrast.1 The aim of this literature review is to appraise the 
available reports on the use of SPECT-CT on lesion categorization as well as review 
the impact of SPECT-CT on lesion categorization when compared to conventional 
planar scintigraphy and SPECT imaging. 
 
Radionuclide imaging by the use of SPECT is currently an important component of 
evaluation of various diseases with a high degree of sensitivity due to its ability to 
provide functional information early in the disease even before morphological 
changes become visible on other imaging modalities.2,3 However, the limited spatial 
resolution of SPECT necessitated the introduction of X-ray based computerized 
tomography which has superior spatial resolution and provides morphologic 
information that helps in better localization of lesions seen on functional and 
metabolic imaging. This form of hybrid imaging has improved the staging of disease 
as well as the prognostic and treatment monitoring potentials of the functional and 




There is dearth of literature reporting the utility, sensitivity, specificity and accuracy 
of this imaging technique as it applies to non-skeletal nuclear medicine 
examinations. This was attributed to slower growth of SPECT-CT when compared to 
PET-CT.4 
 
In a report of initial two-year clinical experience with SPECT-CT by Jacene et al, 54% 
of the cases studied had additional information for image interpretation derived 
from the fusion of the SPECT with the CT images mostly as a result of improved 
localization of abnormal and physiologic SPECT findings by the CT data.4 This study 
also reported improved diagnostic certainty in 24% of the cases and beneficial 
alteration of image interpretation in 13% of the cases. However, some of the 
limitations reported in this study included the low-resolution single-slice CT used 
which did not reveal the exact anatomical sites of abnormal radiotracer 
accumulation especially in the interpretation of abdominal findings on 111In-
Pentetreotide scans, as well as the prolonged CT acquisition time of 10-15 minutes 
by the single-slice scanners that resulted in increased patient motion and 
degradation of image quality. Prolonged acquisition time has been addressed by the 
recent introduction of multi-slice CTs in newer versions of the SPECT-CT systems.5 
Therefore, the increasing availability of new hybrid SPECT-CT imaging equipment 
with advanced technology offers the opportunity to shorten image acquisition time 




Over the years, the main advantages of hybrid SPECT-CT imaging included accurate 
localization and characterization of endocrine and neuroendocrine tumors, solitary 
pulmonary nodules, lung cancers, brain tumors, lymphoma, prostate cancer, 
malignant and benign bone lesions, sentinel lymph node localization as well as 
precise definition of the diagnostic and prognostic profile of cardiovascular 
patients.5 Hybrid imaging using SPECT-CT can improve the staging, prognostic and 
treatment-monitoring potential of the functional and metabolic information 
provided by nuclear medicine tests. Adaptation of the CT field of view to foci of 
increased bone metabolism in a technique referred to as SPECT-guided CT has been 
shown to accurately classify previously indeterminate lesions on planar and SPECT 
imaging in the axial skeleton with certainties of 92% to 100%.6–8 These studies 
limited their observations to the evaluation of foci of increased bone metabolism 
classified as indeterminate on SPECT in cancer patients, therefore inclusion of other 
systems in the evaluation of the clinical value of SPECT-CT is likely to reveal some of 
its potentials. 
 
In a retrospective study of 57 SPECT-guided CTs done by Römer et al.7 among 
cancer patients referred for bone scintigraphy who showed foci of increased 
metabolism, 52 foci (91%) were classified as indeterminate lesions on SPECT alone. 
Of these indeterminate SPECT findings, 63% were correlated with benign findings 
following the application of CT. Majority of these benign findings included 
osteochondrosis, spondylosis and spondylarthosis of the spine. With the application 
of CT in this study, 29% of the lesions were categorized as osteolysis or sclerotic 
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metastasis.7 Nevertheless, 8% of the lesions still remained indeterminate despite 
application of CT. These lesions were mainly in the ribs and the scapula. This study 
was able to clarify more than 90% of the SPECT findings otherwise classified as 
indeterminate in an analysis that was masked to pretest clinical probability and the 
planar scan findings.  
  
Strobe et al.8 in a prospective study assessed the performance of planar bone 
scintigraphy compared with SPECT and SPECT fused with CT in the characterization 
of focal bone lesions in the axial skeleton. This study evaluated the visibility of 
lesions, diagnostic performance, certainty in diagnosis and performance for specific 
diagnoses using histologic, MRI and clinical follow-up findings as reference 
standards. This study revealed sensitivity and specificity for differentiation of 
benign and malignant bone lesions were respectively 82% and 94% for planar 
scintigraphy, 91% and 94% for SPECT, and 100% and 100% for SPECT fused with 
CT. This study also showed that SPECT fused with CT significantly (p= 0.004) 
increased certainty in diagnosis when compared with planar scintigraphy or SPECT 
and as such was considered as the best tool for making a specific diagnosis.8 
 
In a review by Mohan et al on the assessment of the additional value of SPECT-CT 
amongst patients referred from the orthopaedic clinics, it was observed that when 
compared with planar imaging, SPECT-CT provided additional information in 81% 
of the patients.9 SPECT-CT provided specific diagnosis in 46% of the patients in this 
series, and more accurate localization of degenerative or post-surgical changes in 
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the remaining 54% of the patients. This is similar to findings by Langroudi et al and 
Mohan et al, in studies comparing SPECT-CT with planar imaging in the evaluation 
of foot and ankle pathology.10,11 Images acquired with a 16-slice CT were used in 
these studies.  
 
Ndlovu et al reported a SPECT-CT accuracy of 52% in a study of cancer patients with 
equivocal lesions on planar bone imaging for skeletal metastases.12 This study 
showed significant reduction in proportion of lesions (p= 0.0001) and patients 
(p=0.0015) with equivocal findings on planar scintigraphy following the utilization 
of SPECT-CT and therefore, recommended the utilization of SPECT-CT in the 
evaluation of equivocal lesions in instances where correct classification of lesions is 
expected to alter the patient’s management regardless of the tumor primary or 
presence of bone pain. The type of CT scanner used in this study was not mentioned. 
 
Recently in a study by Palmedo et al.13 designed to prospectively assess the 
additional value of SPECT-CT of the trunk used in conjunction with conventional 
nuclear imaging and its effects on patient management in a large patient series, it 
was observed that the sensitivities, specificities, and negative and positive 
predictive values on a per-patient basis were 93%, 78%, 95% and 59% for planar, 
94%, 71%, 97% and 53% for SPECT, and 97%, 94%, 97% and 88% for SPECT-CT, 
respectively. The specificity and positive predictive value were significantly (p < 
0.01) better with SPECT-CT in all subgroups. SPECT-CT improved diagnostic 
accuracy for defining the extent of multifocal metastatic disease in 34.6 % of the 
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patients in this study. Therefore, it was concluded that SPECT-CT had a significant 
effect on clinical management because of correct down staging and upstaging, better 
definition of the extent of metastases, and a reduction in further diagnostic 
procedures. 
 
In a review of the synergistic value of SPECT-CT fusion to radioimmunoscintigraphic 
imaging (RIS) of prostate cancer, Sodee et al.14 opined that 111In-Capromab 
Pentetide (ProstaScint) SPECT-CT imaging can be used not only to identify primary, 
metastatic and prostate cancer recurrence but also to guide external beam radiation 
therapy (EBRT), intensity modulated radiation therapy (IMRT), and brachytherapy 
as well as to monitor treatment of the disease. This corroborated the earlier 
observations by Jana and Blaufox15 that, there is a possibility of ProstaScint scan in 
conjunction with CT in a SPECT-CT scanner in increasing the accuracy of this tracer. 
Kizu et al.16 reported an accuracy of 87.1% after using SPECT and fused 
multidetector CT images for the localization of pelvic sentinel nodes in 11 patients 
with prostatic carcinoma. Similarly, Zhang et al reported SPECT-CT to be superior to 
planar imaging in the detection of SNs in 27 patients with early stage cervical cancer 
scheduled for radical hysterectomy and total pelvic lymphadenectomy.17 This was 
attributed to the exact anatomical localization of the sentinel node. 
 
Report of comparison of planar imaging with SPECT/16-multislice CT (MSCT) 
among paediatric patients by Andersen et al, showed that additional structural 
information was gained in 93% of the cases and additional nuclear medicine 
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information was gained in 80% of the cases, while specific information for biopsy 
guidance was gained in 40% of the cases studied.18 
 
In a study by Filippi and Schillaci19 carried out to assess the usefulness of hybrid 
SPECT-CT in Tc99m-HMPAO labeled leukocytes scintigraphy for bone and joint 
infections, SPECT-CT provided accurate anatomic localization of all positive foci and 
also provided significant additional contribution with regards to the final diagnosis 
in 10 of the 28 patients (35.7%) studied. SPECT-CT differentiated soft tissue from 
bone involvement both in patients with osteomyelitis and in patients with 
orthopaedic implants. It allowed correct diagnosis of osteomyelitis in patients with 
structural alterations after trauma and identified synovial infection without 
prosthesis involvement in patients with knee implant. In a similar study using 
Tc99m-labeled antigranulocyte antibodies Horger et al.20 reported that SPECT-CT 
improves the accuracy of immunoscintigraphy for the diagnosis of chronic 
osteomyelitis, especially in discriminating soft tissue from bone involvement.  
 
In the assessment of the incremental value of SPECT-CT versus planar imaging using 
131I SPECT-CT in the follow-up of differentiated thyroid carcinoma Spanu et al.21 
observed that SPECT-CT correctly characterized 48 foci unclear on planar imaging 
and also defined the location and extent of these foci. SPECT-CT was a determinant 
in classifying as neoplastic those foci for which planar imaging seemed to exclude 
malignancy, discriminating between residue and lymph node metastases in the 
neck, some of which were adjacent to the salivary glands and had been missed on 
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planar scintigraphy. This study showed that SPECT-CT had an incremental value 
over planar imaging in 67.8% of patients, modified therapeutic management in 
35.6% of positive cases, and avoided unnecessary treatment in 20.3% of patients 
with only single benign lesions or physiologic uptake.  
 
Tharp et al.22 also demonstrated that SPECT-CT had an incremental diagnostic value 
for 58% of the patients studied. SPECT/CT improved the characterization of 
indeterminate findings as definitely benign in 13% of patients and the precise 
localization of metastases to the skeleton in 17% of patients, and to the lungs versus 
the mediastinum in 7% of patients. SPECT-CT further optimized the localization of 
radioiodine uptake to nodal metastases versus remnant thyroid tissue. Overall, 
additional findings at SPECT-CT had an effect on management for 41% of patients 
by influencing referral for 131I treatment, tailoring of the administered radioiodine 
dose, and/or the addition of surgery or external radiation therapy when indicated. 
The findings are similar to those by Ruf et al.23 who reported that SPECT-CT 
correctly classified most radioiodine-avid foci as benign or malignant, provided a 
superior anatomical localization for 44% of lesions, and modified the therapeutic 
procedure in 25% of patients. 
 
Krausz and co-workers reported that Tc99m-MIBI SPECT-CT of the parathyroid 
glands contributed to the localization of parathyroid adenomas in patients with 
primary hyper-parathyroidism, and to planning the surgical exploration in 39% of 
patients, predominantly those with ectopic para-thyroid adenomas or who had 
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distorted neck anatomy.24 This is in agreement with the findings by Serra et al.25 
who examined the role of SPECT-CT in the preoperative assessment of 
hyperparathyroid patients and reported that SPECT-CT provided additional data in 
39% of lesions and modified the surgical approach in 19% of patients with retro-
tracheal glands. 
 
Hillel et al in a study of 29 patients most of whom had a diagnosis of carcinoid and 
were referred for 111In-pentetreotide somatostatin receptor imaging (SRI) with 
SPECT-CT, 64% of the abnormal foci were established to be previously unknown 
location while SPECT-CT changed the location of at least one lesion in 36% of the 
cases.26 This study concluded that the application of SPECT-CT in what was referred 
as functional anatomic mapping (FAM) can improve the reporting accuracy for 
SPECT SRI with significant impact on patient management. In a similar study by 
Castaldi et al.27 involving 54 patients with known or suspected neuroendocrine 
tumour (NET), SPECT-CT improved image interpretation in 23 cases, provided 
precise anatomical localization of increased tracer uptake in 20 cases and disease 
exclusion in sites of physiological uptake in 5 cases. SPECT-CT also allowed 
definition of the functional significance of lesions detected by diagnostic CT in 10 
patients in addition to the modification of clinical management in 14 cases by 
changing the diagnostic approach in 8 and the therapeutic modality in six. Krausz et 
al, reported that SPECT-CT affected the diagnostic interpretation in 32% of patients 
with known or suspected NETs and resulted in changes in management in 14% by 
altering the surgical approach, sparing unnecessary surgery, and/or modifying the 
 
 28 
therapeutic modality.28 Pfannenberg et al.29 reported that, therapy was modified in 
28% of patients owing to the results of image fusion: in 5 patients tumor could be 
excluded, in 3 patients the individuals were spared unnecessary surgery due to 
detection of additional lesions indicating systemic tumor spread, in 4 patients the 
surgical approach was modified owing to precise tumor localization and 
minimization of the surgical field, and in 2 patients medical and radio-peptide 
therapy was modified. 
 
In the evaluation of the added value of SPECT-CT for the correlation of MIBG scan 
and diagnostic CT in neuroblastoma and pheochromocytoma, Rozovsky et al.30 
reported that SPECT-CT provided additional clinical information in 53% of the 
cases. SPECT-CT differentiated between bilateral symmetric upper thoracic activity, 
probably related to physiological muscular or brown fat uptake, and malignant 
lesions, such as skeletal metastases in the scapula, ribs, or malignant supraclavicular 
lymphadenopathy. 
 
Lerman et al.31 assessed whether SPECT-CT improves sentinel node identification in 
overweight patients. In this study, SPECT-CT accurately identified sentinel nodes 
(SN) in 75% of patients for whom the identification of SNs by the intraoperative 
blue dye technique failed. Even-Sapir et al.32 and Lerman et al.33 have reported that, 
SPECT-CT data allowed the detection of ‘‘hot’’ nodes missed by planar imaging, 
excluded sites of false-positive non-nodal uptake, and accurately localized axillary 
and extra-axillary hot nodes. These studies also agree with the findings by Husarik 
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and Steinert34 who evaluated the clinical use of integrated SPECT-CT in the 
identification of the sentinel lymph nodes in patients with operable breast cancer. 
This study showed that localization and identification of sentinel lymph nodes was 
more accurate by integrated SPECT-CT imaging in comparison with planar images 
and SPECT images, respectively. SPECT-CT showed more accurate information in 
82% of the patients by demonstrating the exact anatomical information needed to 
assign the SN levels according to the American Joint Committee on Cancer (AJCC). 
SNs close to the injection sites that were not visible on planar images due to scatter 
radiation were detected with SPECT/CT in 14% of the patients. This is in agreement 
with the findings by Even-Sapir et al and Lerman et al.32,33 
 
Kretschmer et al found SPECT-CT to be an excellent tool to anatomically localize the 
SN in malignant melanoma draining to the pelvic region.35 Garcia-Burillo et al.36 
prospectively assessed the impact of SPECT-CT sentinel lymph node identification in 
papillary thyroid cancer with respect to lymphatic staging and surgical management 
improvement. This study showed that, lymphoscintigraphy revealed at least one 
sentinel lymph node (SLN) in 19 of 24 patients (79 %) on planar and SPECT-CT 
images, as well as in 23 of 24 patients (96 %) during surgery using a hand-held 
gamma probe. SPECT-CT detected latero-cervical drainage in a significant 
percentage of patients, thereby allowing the detection of occult lymph node 
metastases and improving the surgical management in patients with papillary 
thyroid carcinoma (PTC). In a similar study Wagner and co-workers evaluated 
SPECT-CT topographic mapping of SNs before gamma-probe guided biopsy in 30 
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patients with head and neck squamous cell carcinoma and found that SPECT-CT 
enhances anatomical orientation and diagnostic sensitivity with more detected SNs 
than by planar lymphoscintigraphy.37  
 
Schillaci O et al evaluated the usefulness of RBC SPECT and transmission computed 
tomography (RBC SPECT-CT) performed simultaneously with a hybrid imaging 
system for correct characterization of hepatic lesions in patients with suspected 
haemangioma, and assessed the additional value of fused images compared with 
SPECT alone. SPECT-CT had a significant impact on results in 33.3% of the patients 
with four lesions defined as indeterminate on SPECT images, accurately 
characterizing the hot spot foci located near vascular structures.38 
 
The applicability of single photon emission computed tomography-computed 
tomography (SPECT-CT) in patients with acute lower gastrointestinal bleeding 
undergoing scintigraphy with 99mTc-labelled red blood cells (RBC), and assessment 
of the additional clinical value of fused images when compared to the standard 
radionuclide scan were evaluated by Schillaci and co-workers.39 In this study, 
SPECT-CT had significant impact on the scintigraphic results in 7/19 patients 
(36.8%), it precisely localized the bleeding foci whose location could not be 
identified in standard scans in 6 patients, and in one it excluded the presence of an 





 This literature review has shown that fusion of functional information 
obtained from radionuclide imaging with morphologic information obtained from x-
ray computerized tomography has improved lesion localization, characterization 
and diagnostic accuracy. 
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3.0 JOURNAL ARTICLE 
(See appendix III for SA Journal of Radiology Author guidelines) 
Title: Assessment of the impact of application of single photon emission 
computerised tomography and SPECT-CT on lesion categorisation in bone 
scintigraphy. 
3.1 Abstract 
Objectives: To assess initial experience with the use of a new SPECT-CT in the 
evaluation of lesions. 
Methods: The folder number, radiopharmaceutical used and type of scan of patients 
examined with a new Siemens T6 SPECT-CT between 2 April and 31 December 2013 
were retrieved. The number of 99mTc-MDP bone scans was sufficient for a detailed 
analysis. The scans were re-processed and reported by the observer before he was 
given any clinical information.  Whole body planar, whole body planar plus SPECT 
and whole body planar plus SPECT-CT images were assessed successively in three 
separate sessions at least two weeks apart.  At each session, the certainties of 
detection, localisation, and categorisation of each lesion were recorded. 
Results: A total of 539 lesions were seen on the whole body, SPECT and CT images 
in 133 patients.  The whole body images showed no lesions in three patients and 
378 lesions in 130 patients, 117(31%) lesions in areas not covered by the SPECT. 
SPECT detected 122 additional lesions in 79 patients. Thirty-nine (12.2%) lesions 
were seen only on CT in 32 (24.1%) patients.  
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For the 261 lesions seen on the planar images in the SPECT FOV, lesion detection 
was definite in 233 (89.3%), localisation definite in 151(57.9%) and categorisation 
definite in 123 (47.1%) lesions. On the SPECT, definite lesion detection, localisation 
and categorisation were recorded respectively for 259 (99.2%), 228 (87.4%) and 
176 (67.4%) of the 261 lesions. Lesion detection, localisation and categorisation 
certainties were definite for 100%, 99.1% and 94.7% of the SPECT-CT lesions 
respectively.  
Conclusion: Whole body planar scintigraphy is essential in lesion detection. SPECT 






The use of hybrid imaging consisting of Single Photon Emission Computerised 
Tomography (SPECT) and X-ray transmission Computerised Tomography (CT) scan 
is increasing globally. It has the advantage of providing functional and morphologic 
information for a given lesion. Radionuclide imaging has high sensitivity early in the 
disease before morphological changes become visible on other imaging modalities.1 
The addition of CT provides morphological information with high spatial resolution.   
The combination of SPECT and CT has improved staging of disease as well as the 
prognostic and treatment monitoring potentials of the functional and metabolic 
information provided by conventional nuclear medicine examinations.2,3  
 
Over the years, the use of SPECT-CT has been shown to accurately re-classify lesions 
previously classified as indeterminate on planar and SPECT imaging in both skeletal 
and non-skeletal nuclear medicine examinations with certainties of 88% to 100%.4–7 
However, the limitations in previous studies included the low-resolution of the CT 
used which did not reveal the exact anatomical sites of abnormal radiotracer 
accumulation, and the prolonged CT acquisition time of 10-15 minutes by the dual 
slice CT scanners that resulted in increased patient motion and degradation of 
image quality.8 Prolonged acquisition time and poor spatial resolution have been 
addressed by the recent introduction of multi-slice CT scanners in newer versions of 




A new SPECT machine integrated with a helical 6-slice CT was installed in the 
Department of nuclear medicine at Groote Schuur Hospital in March 2012. The 
objectives of this study were to assess the initial experience with the use of SPECT-
guided CT in the evaluation of lesions; the impact of the addition of 6-slice CT in 
SPECT-CT on lesion categorisation, and the difference between the use of SPECT 




Approval for the study was obtained from the Research Ethics Committee of the 
Faculty of Health Sciences University of Cape Town and Groote Schuur Hospital (Ref 
613/2013, see approval in appendix IV). All of the scans were done for diagnostic 
purposes and the initial reports issued used for patient management. 
  
The folder number, radiopharmaceutical used and type of scan of all patients 
examined on the new stand-alone Siemens T6 SPECT-CT (Siemens Medical Solutions 
SW, Erlangen) machine between 2 April 2012 and 31 December 2013 were 
retrieved from the electronic archives of the Nuclear Medicine Department. SPECT-
CTs done for myocardial perfusion and cerebral perfusion were excluded from the 
analysis. In patients who had multiple studies, only the first study was included. The 
number of bone scans was deemed sufficient for a detailed analysis. 
 
Each patient had planar whole-body and selected static images. SPECT and 
subsequently CT images of the region of clinical interest were recorded depending 
on the abnormalities seen on the initial images or the indication for the study as 
deemed fit by the supervising Nuclear Medicine registrar or consultant at the time 
of image acquisition.  
 
Whole body images were acquired using a low energy high-resolution collimator 
with a matrix size of 256 x 256 and a scan speed of 14cm per second. SPECT images 
were obtained using a 128 x 128 matrix with 25 seconds per step acquiring 64 
 
 43 
projections with 1800 rotation for each gamma camera head. CT images were 
acquired using a low dose protocol without intravenous contrast administration. 
The low dose CT parameters used were: 2.5-30mAs, 120 kV, slice thickness of 1.25-
5mm and pitch of 1.2-1.5.  
 
SPECT images were reconstructed using the Flash 3D ordered subset expectation 
maximization (OSEM) iterative reconstruction algorithm in four subsets and eight 
iterations, and smoothed with a spatial Gaussian filter 6.0 (FWHM). The CT images 
were reconstructed using high-resolution reconstruction algorithms (B08s kernel) 
while the images were viewed using the Siemens B80s kernel, for bone and B31s 
kernel for soft tissues.  
 
For the purposes of this study, all examinations were re-processed and reported on 
the Siemens (Syngo VE32B, 2008, Siemens Medical Solutions, SW, Erlangen) and 
HERMES (version V1.0, 2005, Hermes Medical Systems, Sweden) physicians’ 
workstations. During the reconstruction and review of the images for this study, the 
observer was blinded to the history, clinical examination findings, laboratory and 
histology results as well as the previous reports issued. The location and level of 
diagnostic certainty were recorded for each lesion. A four-point score was assigned 
for each lesion for the certainty of lesion detection, localisation and categorisation 
(Table 1). The lesions were assessed successively in separate reading sessions on 
planar, planar plus SPECT and planar plus SPECT-CT images with at least two weeks 
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in between the sessions. The information on patient demographics and indications 
for the study were made available for the observer.  
Table 1: Scores for certainty of lesion detection, localisation and categorisation. 
Score Certainty Description 
0 Unknown Don’t know 
1 Possible Might know 
2 Probable Have a good idea 
3 Definite Sure 
Data analysis was performed on per lesion and per patient basis. Assessments were 
made on per lesion and per patient bases for lesion detection, localisation, and 
categorisation.  Analysis of levels of certainty for lesion detection, localisation and 




Within the period under review, 2 April 2012 to 31 December 2013, 241 SPECT-CT 
scans were done. The type of scan and radiopharmaceutical used in the 185 studies 
left after exclusion of 50 follow-up scans, 4 technically poor quality studies and 2 
with an incomplete dataset are summarized in Table 2.  
 
Table 2: Distribution of cases according to radiopharmaceuticals. 
Radiopharmaceutical Indication Number 
99mTc-MDP Metastatic survey  57 
 Musculoskeletal pain 39 
 Infection/inflammation 22 
 CRPS* 4 
 Other 11 
 Sub-total Bone scans 133 
123I-Sodium iodide Thyroid carcinoma metastatic survey 21 
123I-Sodium iodide  Ectopic thyroid tissue 1 
131I-Sodium iodide  Thyroid carcinoma metastatic survey 5 
131I-Sodium iodide  Post-therapy metastatic survey 1 
123I-mIBG Evaluation for 
paheochromocytoma/paraganglioma 
3 
67Ga-Gallium citrate Infection/inflammation 7 




99mTc-Octreotide Evaluation for neuroendocrine 
tumours 
2 
99mTc-RBC Evaluation for liver 
haemangioma/splenic remnant 
6 
Total  185 




The 133 patients referred for 99mTc-MDP bone scintigraphy comprised 92 (69.2%) 
females and 41 (30.8%) males with a mean age of 53.3 ± 15.7 years. Majority of the 
patients were referred for metastatic survey (42.9%), or because of musculoskeletal 
pain (29.3%) or suspected infection/inflammation (16.5%). A total of 539 lesions 
were seen on the whole body, SPECT and CT images (Table 3).  
 
Table 3: Lesions detected on 99mTc-MDP bone scan. 
 Lesions Patients  
(n=539) (n=133) % 
Whole body images 378  130§  
 
97.7 
     Outside SPECT FOV  117  64  48.1 
     In SPECT FOV  261  128 96.2 
 
     In CT FOV  197  115 86.5 
 
SPECT images  383  133  
 
100 
     In CT FOV  279  124  
 
93.2 
SPECT-CT images 318  133 100 
 
     Both SPECT & CT 171  73 54.9 
     SPECT only 108  60  45.1 
     CT only 39  32  24.1 
FOV: field of view.  
§No lesions were seen on the whole body images in three patients. 
 
There were three patients in whom no lesions were seen on the whole body images. 
SPECT and SPECT-CT were done because of clinical information: one patient was a 
49 year old female with breast carcinoma who complains of back pain; the second 
patient was a 28 year old female with three month history of wrist pain, while the 
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third patient was a 39 year old female with history of injury to the right knee four 
weeks prior to presentation. In the remaining 130 patients 378 lesions were 
detected on the whole body images, 261(69.0%) lesions within the field of view 
(FOV) of the SPECT images and 117(31%) in areas not covered by the SPECT. SPECT 
detected a total of 383 lesions in 133 patients, 122 (31.9%) of the lesions were not 
seen on the whole body images. These additional lesions were detected in 79 
patients. SPECT-CT detected 318 lesions in 133 patients, 171 (53.8%) lesions were 
seen on SPECT and CT, 108 (34.0%) lesions on SPECT only, and 39 (12.2%) lesions 
on CT only. The 39 additional lesions were detected in 32 (24.1%) patients.  
 
On planar images, lesion detection certainty was definite for 346 (91.5%), probable 
for 30 (7.9%) and possible for 2 (0.6%) lesions (Table 4). Lesion localisation and 
categorisation certainties were respectively 63.5% and 53.9% definite, for the 
lesions detected on the whole body images (Tables 5 and 6).   
 
Table 4: Lesion detection certainty. 
WB: whole body 
Certainty, n (%) Possible Probable Definite Total 
WB images  2(0.6)   30(7.9)  346(91.5)  378 (100) 
Planar SPECTFOV 0 (0) 28(10.7) 233(89.3) 261 (100) 
SPECT images 0 (0) 2 (0.5) 381(99.5) 383 (100) 
SPECT in CTFOV 0 (0) 0 (0) 279(100) 279 (100) 
SPECT-CT images 0 (0)  0 (0) 301(94.7) 318 (100) 
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Table 5: Lesion localisation certainty. 
WB: whole body 
 
Table 6: Lesion categorisation certainty.  
WB: whole body 
 
For the 261 lesions seen on the planar images in the SPECT FOV, lesion detection 
was definite in 233 (89.3%), localisation was definite in 151(57.9%) and 
categorisation was definite in 123 (47.1%) lesions. On the SPECT, definite lesion 
detection, localisation and categorisation were recorded for 259 (99.2%), 228 
(87.4%) and 176 (67.4%) of the 261 lesions respectively (Table 7). 
Certainty, n (%) Possible Probable Definite Total 
WB images  0(0)   138(36.5)  240(63.5)  378 (100) 
Planar SPECTFOV  0(0) 110(42.1) 151(57.9) 261 (100) 
SPECT images 0(0) 55 (14.4) 328(85.6) 383 (100) 
SPECT in CTFOV 0(0) 3 (1.1) 276(98.9) 279(100) 
SPECT-CT images 0(0)  3(0.9) 315(99.1) 318(100) 
Certainty, n (%) Possible Probable Definite Total 
WB images  2(0.6)   172(45.5)  204(53.9)  378 (100) 
Planar SPECTFOV 2 (0.8) 136 (52.1) 123 (47.1) 261 (100) 
SPECT images 0(0) 116 (30.3) 267 (69.7) 383 (100) 
SPECT in CTFOV 0(0) 17(6.1) 262(93.9) 279(100) 
SPECT-CT images 0(0)  17(5.3) 301(94.7) 318(100) 
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Table 7: Certainty scores for planar lesions seen on SPECT. 
Certainty, n (%) Possible Probable Definite Total 
Detection 0(0) 2 (0.8) 259 (99.2) 261 (100) 
Localisation 0(0) 33 (12.6) 228 (87.4) 261 (100) 
Categorisation 0(0) 85 (32.6) 176 (67.4) 261 (100) 
On SPECT, out of the 383 lesions detected the certainty of lesion detection, 
localisation and categorisation were definite for 381 (99.5%), 328 (85.6%) and 267 
(69.7%) lesions respectively. For the 279 SPECT lesions seen in the CT FOV in 124 
patients the lesion detection, localisation and categorisation was definite in 279 
(100%), 276 (98.9%) and 262 (93.9%) lesions respectively. 
Lesion detection certainty was definite for all the 318 (100%) SPECT-CT lesions, 
while lesion localisation and categorisation certainties were definite in 99.1% and 
94.7% of the lesions respectively. 
Of the 42 lesions categorised as indeterminate on planar, 20/42 (47.6%) and 35/42 
(83.3%) were re-categorized following the addition of SPECT and SPECT-CT 
respectively (Table 8). There were 78 (39.6%), 88 (44.7%) and 93 (47.2%) lesions 




Table 8: 99mTc-MDP scintigraphy categorisation of lesions in CT FOV. 
Lesion category Planar alone 
n (%) 
Planar + SPECT 
n (%) 
Planar + SPECT-CT 
n (%) 
Indeterminate  42 (21.3) 22 (11.2) 7 (3.6) 
Metastasis 16 (8.1) 19 (9.6) 17 (8.6) 
Degenerative 78 (39.6) 88 (44.7) 93 (47.2) 
Infection/Inflammation 
(Bone/Joints)* 
47 (23.9) 49 (24.9) 51 (25.9) 
Infection/Inflammation 
(Soft tissues)** 
1 (0.5) 2 (1.0) 2 (1.0) 
Others*** 13 (6.6)  17 (8.6) 27 (13.7) 
Total 197 (100) 197 (100) 197(100) 
* Arthritis, Charcot’s, osteomyelitis, discitis, arthropathy, spondylosis, enthesopathy, 
pseudoarthrosis. 
** Cellulitis, adenopathy. 
*** Fracture, non-union, malunion, haemangioma, avascular necrosis, enchondroma, 








This study reports the initial experience with new multi-slice SPECT-CT scanner and 
the impact of the addition of SPECT with low dose CT in the evaluation of lesions in 
patients referred for 99mTc-MDP bone scintigraphy.  
The need to perform planar whole-body imaging prior to SPECT image acquisition is 
demonstrated in this study by the finding of 31% of lesions in areas not covered by 
the SPECT. This is in addition to the fact that, on planar images, the detection of 
more than 91% of the 378 lesions seen was certain. These findings underscore the 
role of whole-body planar scintigraphy as the mainstay for the detection of skeletal 
metastases for more than 40 years.9,10 Therefore, these findings emphasize the value 
of performing planar whole body images before proceeding with SPECT and 
subsequently SPECT-CT image acquisition. 
This study shows that SPECT not only improved the ability of radionuclide imaging 
to detect lesions by revealing 31% more lesions, it also increased observer’s 
confidence regarding lesion localisation. This is in agreement with earlier reports 
that showed SPECT is more sensitive than planar in detecting and localising lesions, 
particularly vertebral lesions with a 20%-50% increase in lesion detection.1,11,12 The 
addition of SPECT has been shown to increase the accuracy of lesion categorisation 
by improving localisation, especially in complex skeletal structures such as spine, 
skull and pelvis.1,13 In this study, the addition of SPECT has markedly improved the 
observer’s confidence with regards to lesion detection, localisation and 
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categorisation by increasing certainty from 89.3% to 99.2%, 57.9% to 87.4% and 
47.1% to 67.4% respectively when compared with planar imaging. 
The addition of CT detected 39 more lesions in 24% of the patients while SPECT-CT 
markedly increased the interpreter’s confidence with respect to lesion localisation 
and categorisation from 85.6% to 99.1% and 69.7% to 94.7% respectively in 
comparison to SPECT and planar images. This agrees with the reports from other 
studies.2,4–7,14,15 In addition, some of these studies reported marked reduction of 
indeterminate lesions from a rate of between 48% and 72% using whole-body 
planar scintigraphy with or without SPECT, to a rate between 0% and 15%.4–6 The 
current study showed a reduction in the indeterminate lesion rate among patients 
referred for 99mTc-MDP bone scintigraphy from 21.3% on planar alone to 11.2% and 
3.6% following the addition of SPECT and SPECT-CT respectively. While the 
proportion of SPECT-CT indeterminate lesions is similar to that found in the study 
reported by Palmedo et al15, the lower rate found on the planar images in the 
current study may be due to the criteria used when referring patients for 
scintigraphy. 
The CT component of the hybrid imaging SPECT-CT systems can assist in the 
diagnosis of benign skeletal findings, such as osteophytes or degenerative changes, 
or haemangiomas causing abnormal tracer uptake in patients referred for 
metastatic survey. However, it is important to note that foci of increased tracer 
uptake on bone scintigraphy due to metastatic bone lesions may not show any 
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morphologic abnormality on CT. Likewise lytic bone lesions with increased tracer 
uptake on bone scintigraphy may only be visualised on CT after they have destroyed 
50-75% of the trabecular bone.1,3,4,11 Therefore under these circumstances the lack 
of anatomical abnormalities despite abnormal tracer uptake suggests medullary 
disease, hence the need to have the SPECT-CT images. Improved lesion 
categorisation on SPECT-CT makes a difference with regards to patient management 
decisions especially in patients referred for skeletal survey for metastases or 
musculoskeletal pain in patients with known malignancy.4–7,11,15 
 
Some of the limitations of this study include the retrospective nature of the study as 
well as the lack of an independent standard such as histological correlation, or, 
clinical or imaging follow-up.  
 
In conclusion, this study has shown that whole body planar scintigraphy is essential 
in lesion detection while SPECT improves lesion detection and observer’s 
confidence regarding lesion localisation. The use of SPECT-CT showed marked 
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